No phaseRecruiting

Study on the Management of COMISA (COMISA-PEC)

Sponsor
University Hospital, Grenoble (Academic or other)
Enrolment
150 planned
Conditions
Obstructive Sleep Apnea (OSA); Insomnia; COMISA
Interventions
Daridorexant 50 mg; Continuous Positive Air Pressure (CPAP)
Ages
adults, older adults
Registry
NCT07743931

From the registry

COMISA, the combination of obstructive sleep apnea (OSA) and insomnia, is a frequent and burdensome condition. Many patients with OSA experience clinically significant insomnia symptoms, and a substantial proportion of individuals with chronic insomnia also meet criteria for OSA. This comorbidity is associated with more severe symptoms, more complex diagnostic pathways, and reduced adherence to continuous positive airway pressure (CPAP) therapy. This study aims to better understand COMISA and evaluate whether adding daridorexant to CPAP treatment can improve treatment adherence and overall patient outcomes.

Primary outcomes

  • To evaluate, in patients diagnosed with COMISA and treated with CPAP, the impact of daridorexant on CPAP adherence at 4 months compared with patients not receiving daridorexant.
Full record on ClinicalTrials.gov